Akari Therapeutics plc ADS (NASDAQ: AKTX)
$3.61
+0.1100 ( +3.14% ) 16.6K
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).
Market Data
Open
$3.61
Previous close
$3.50
Volume
16.6K
Market cap
$43.91M
Day range
$3.51 - $3.73
52 week range
$1.08 - $5.50
SEC Fillings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| 8-k | 8K-related | 14 | Jun 04, 2024 |
| def | Proxies and info statements | 8 | Jun 03, 2024 |
| 8-k | 8K-related | 12 | May 16, 2024 |
| 10-q | Quarterly Reports | 58 | May 15, 2024 |
| 8-k | 8K-related | 11 | May 07, 2024 |
| 4 | Insider transactions | 1 | May 03, 2024 |
| 8-k | 8K-related | 13 | May 01, 2024 |
| 4 | Insider transactions | 1 | Apr 30, 2024 |
| 8-k | 8K-related | 11 | Apr 11, 2024 |
| 8-k | 8K-related | 12 | Apr 01, 2024 |